Sleep & insomnia
StudyCommunity
Study: Small historical controlled studies measured sleep; the insomnia result was weak.12
Community: Nightly subcutaneous use is reported, distinct from the IV studies.5
Mind & sleep
DSIP
Delta sleep-inducing peptide
No FDA-approved DSIP/emideltide product identified.
What does it do?
Molecular information
7Amino-acid sequence
- Trp
- Ala
- Gly
- Gly
- Asp
- Ala
- Ser
- Gly
- Glu
9 residues · N → C7
Length9 amino acids
Molecular weight · Da848.8 Da
Molecular formulaC35H48N10O157
W–A–G–G–D–A–S–G–EValues refer to the parent peptide; the manufacturer sheet describes acetate material with additional counterion mass.
Pharmacokinetics
Unverified reference estimateNot independently confirmed
Reference half-life8 min14
Route / formulationSource page: Injectable. Exact PK route not verified.
This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 40 min
Five half-lives in this estimated model. This is not a prediction of when effects stop.
About this estimate
Population: Not established by the reference estimate
Source’s stated attribution: Graf et al.
Source’s reported peak time: 30 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Weak insomnia results
The 16-person study found small objective changes and no subjective sleep-quality benefit; its authors considered a major therapeutic effect unlikely.2
Doses & schedules
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| IVIntravenous | 25 nmol/kg | Afternoon administration before each of 3 consecutive nights | Assess chronic-insomnia sleep outcomes16 chronic-insomnia patients, randomized DSIP versus placeboHuman study | 3 nights | 2 |
Population 16 chronic-insomnia patients, randomized DSIP versus placebo Context Historical controlled study; findings did not support a major therapeutic effect. | |||||
| IVIntravenous | 25 nmol/kg | Single dose in randomized crossover sessions | Acute endocrine response11 healthy men aged 25–39Human study | Acute observation | 4 |
Population 11 healthy men aged 25–39 Context Saline-controlled hormone study; not an insomnia treatment protocol. | |||||
| SubQ | 100-200 mcg | Once nightly | Sleep EnhancementReference report | 5-10 consecutive days | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are Pep-Pedia claims, not tested safety findings. Source tabs Injectable | |||||
| SubQSubcutaneous | 250-300 mcg | Daily | Chronic PainReference report | 5-10 consecutive days | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are Pep-Pedia claims, not tested safety findings. Source route wording IV or SubQ Source tabs Injectable | |||||
| IVIntravenous | 250-300 mcg | Daily | Chronic PainReference report | 5-10 consecutive days | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are Pep-Pedia claims, not tested safety findings. Source route wording IV or SubQ Source tabs Injectable | |||||
| SubQ | 150 mcg | Evening | Stress ManagementReference report | 5-10 consecutive days | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are Pep-Pedia claims, not tested safety findings. Source tabs Injectable | |||||
| IVIV preferred | 200-300 mcg | Twice daily | Withdrawal SupportReference report | 5-10 consecutive days | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are Pep-Pedia claims, not tested safety findings. Source tabs Injectable | |||||
| SubQ | 100-150 mcg | Post-training | Athletic RecoveryReference report | 5-10 consecutive days | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are Pep-Pedia claims, not tested safety findings. Source tabs Injectable | |||||
| IntranasalNasal spray | 200-300 mcg | Once at bedtime | Sleep InductionReference report | 7-14 days | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are Pep-Pedia claims, not tested safety findings. Source tabs Nasal | |||||
| IntranasalNasal spray | 150-200 mcg | Twice daily | Stress ReliefReference report | 7-14 days | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are Pep-Pedia claims, not tested safety findings. Source tabs Nasal | |||||
| IntranasalNasal spray | 300-400 mcg | Daily | NeuroprotectionReference report | 7-14 days | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are Pep-Pedia claims, not tested safety findings. Source tabs Nasal | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 5-10 consecutive days
- Break
- 2-4 weeks between cycles
Reported timing
Evening administration 30-60 minutes before intended sleep
Nasal
- Use period
- 7-14 days
- Break
- 2-3 weeks between cycles
Reported timing
30 minutes before intended sleep or as needed for stress
Side effects & safety
Route-specific safety gap
FDA did not identify safety information for the proposed compounded route.
3Immune and impurity concerns
FDA identifies possible immunogenicity and difficulty characterizing peptide impurities.
3Limited study size
Sixteen insomnia patients provide little ability to detect uncommon or long-term adverse effects.
2Sedation and headache
Drowsiness, dizziness, headache; assess impairment before driving.
Stop symptoms
Excess sedation, agitation/insomnia, mood deterioration, distressing dreams or allergy.
Nasal route
Irritation, bleeding, sinus pain/infection; congestion changes absorption.
Pregnancy and long-term safety
Not established; source reassurance about dependence is not proof.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
9 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
GABA agonists
Caution reportedPossible additive sedation.15
Reference report · Pep-Pedia label: Monitor CombinationOpioid medications
Caution reportedUncertain opioid-pathway interaction.15
Reference report · Pep-Pedia label: Use CautionMelatonin
Unverified pairingProposed sleep complement.15
Reference report · Pep-Pedia label: SynergisticCortisol modulators
Unverified pairingProposed stress complement.15
Reference report · Pep-Pedia label: CompatibleSelank
Unverified pairingProposed anxiety/sleep complement.15
Reference report · Pep-Pedia label: SynergisticSemax
Unverified pairingProposed daytime/nighttime pairing.15
Reference report · Pep-Pedia label: CompatibleGrowth hormone peptides
Unverified pairingCombination safety unestablished.15
Reference report · Pep-Pedia label: CompatibleEpitalon
Unverified pairingProposed circadian complement.15
Reference report · Pep-Pedia label: SynergisticSedatives, alcohol and other sleep agents
Not establishedThe cited insomnia study does not establish these combinations as safe. A sleep-related mechanism is not a clinical interaction study.2
Research contextNo matching interactions. Try another name or filter.
Reconstitution calculator
Enter your peptide amount and container size. Get a volume and a simple measurement scale.
Suggested final volume mL
Estimated water to add≈ mL
For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.
1 pen unit (one dial step)=
Amounts below are total blend mass. Ingredient amounts are listed separately.
| Pen units | Amount | Volume |
|---|
Ingredients per unit
Other simple scales
Convert a specific amount
Enter an amount to calculate its volume and device setting.
Calculation & assumptions
The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.
The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.
V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗Reconstitution
A supplier sheet describes laboratory solubility, not a validated human injection preparation.7
Product-specific limits
The Cayman emideltide acetate sheet is for research material; its laboratory handling directions do not establish a bacteriostatic-water volume or injectable beyond-use date.7
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia provides a 1 mg/mL concentration example.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- 1 mg in 1 mL; 100 mcg occupies 0.1 mL (10 U-100 syringe units). · Reported storage: refrigeration after mixing.
The source describes gentle mixing and avoiding vigorous shaking.
Nasal
The nasal section reports a 2 mg/mL solution and pump calibration.
- Reported parameters
- At 0.05 mL per spray, 2 mg/mL gives 100 mcg per spray. · The pump output is a stated assumption, not a universal nasal-spray volume.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite lyophilized powderReported appearanceClear solution when mixedReported variationShort stability periodReported concernYellow or cloudy solutionReported appearanceReputable source essentialReported variationProtect from degradation
15Vial sizes
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Storage notes
15Refrigerate at 2-8°C, protect from light, use within 14 days
Refrigerate spray bottle, keep upright
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Pen & syringe measurements
Device units measure volume. Concentration determines the amount in mg.
1 notch = 0.01 mL
Documented 1-unit V2 models
- One dial increment
- 1 unit
- Cartridge capacity
- 3 mL
- Maximum setting
- 60 units · 0.60 mL
Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.
1 unit = 0.01 mL
100 units = 1 mL
- 10 units
- 0.10 mL
- 30-unit capacity
- 0.30 mL
- 50 / 100-unit capacity
- 0.50 / 1 mL
Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.
Use the mL scale
mL syringes and calibrated pipettes
- 0.01 mL
- 10 µL
- 0.10 mL
- 100 µL
- Amount
- mL × mg/mL
Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.
3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.
Device references
AVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.Evidence limits
View findings →Whether contemporary, adequately powered trials would show meaningful insomnia benefit.1
4 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Research findings
Limited human dataSource context
Interaction categories are Pep-Pedia claims, not tested safety findings.
Compound identity & other names
Delta sleep-inducing peptide has been tested in small sleep experiments. An early positive study was followed by weak results in chronic insomnia; the name should not be mistaken for a demonstrated treatment effect.
Other names: Delta sleep-inducing peptide · Emideltide · DSIP-9
No FDA-approved DSIP/emideltide product identified.
Emideltide / delta sleep-inducing peptide: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu.7
How it may work
Proposed GABA, NMDA, opioid and stress-axis modulation. Nasal brain targeting is a hypothesis, not proven comparative efficacy.15
An early sleep signal in six volunteers
A 1981 double-blind crossover study reported 59% higher median sleep time during a 130-minute window after an IV infusion. This was a very small acute experiment in healthy volunteers.
1Little persuasive benefit in chronic insomnia
In a 1992 study of 16 patients, sleep efficiency and latency showed weak statistical improvements, possibly partly due to changes in the placebo group. Subjective sleep quality did not improve; investigators judged major short-term therapeutic benefit unlikely.
2Endocrine change does not establish sleep benefit
Eleven healthy men showed lower ACTH-like immunoreactivity after IV DSIP, without a corresponding cortisol change. This endocrine experiment did not demonstrate a clinical sleep benefit.
4Research areas and evidence gaps
Sleep and insomnia research. Small historical controlled studies measured sleep; the insomnia result was weak.12
- Whether contemporary, adequately powered trials would show meaningful insomnia benefit.
- Long-term safety and whether subcutaneous community schedules reproduce intravenous trial results.
Additional uses listed by Pep-Pedia
Sleep. Source claims deeper sleep, easier onset and fewer awakenings.15
Mood and stress. Reported anxiety, cortisol and mood effects.15
Pain, hormones and withdrawal. Small historical studies; not established treatment.15
Neurological recovery. Nasal stroke-recovery claims derive from animal models.15
Community reports Unvalidated
PepPedia describes improved deep sleep and easier sleep onset; its optimistic account should be read alongside the weak insomnia trial.5
PepPedia's editorial protocol summary, not measured community consensus. Benefits, product identity, and safety are not independently verified; these reported practices are not recommendations.
Search coverage and review status
No newer clinical paper was verified. Added an older controlled ACTH experiment without treating endocrine changes as a sleep benefit.
- Checked
- 2026-10-12
- Search
- "delta sleep inducing peptide" 2025 2026 study
- Catalog
- Pep-Pedia ↗ · 6 listed references retained
- Targeted search and selected primary-source checks, not an exhaustive systematic review.
- Preserved bibliography entries marked unreviewed have not had their findings independently verified.
AI-prepared summaries. Independent medical editorial review is pending.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
The source hides 5 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Age range
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 31 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 9 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 6 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
The source hides 8 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Would recommend
The source hides 6 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
The source hides 3 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “1578 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
References
Original sources and review status. Open a reference to read its summary.
1Acute and delayed effects of DSIP on human sleepAbstract checked
AI-PREPARED SUMMARY
A six-person crossover experiment found an acute sleep-time signal after intravenous DSIP; applicability to chronic insomnia is limited.
An early sleep signal in six volunteers
A 1981 double-blind crossover study reported 59% higher median sleep time during a 130-minute window after an IV infusion. This was a very small acute experiment in healthy volunteers.
2DSIP in chronic insomnia: double-blind studyAbstract checked
AI-PREPARED SUMMARY
In 16 patients, weak objective changes were not accompanied by subjective sleep-quality improvement; authors found major therapeutic benefit unlikely.
Little persuasive benefit in chronic insomnia
In a 1992 study of 16 patients, sleep efficiency and latency showed weak statistical improvements, possibly partly due to changes in the placebo group. Subjective sleep quality did not improve; investigators judged major short-term therapeutic benefit unlikely.
3FDA: compounding safety concernsPrimary source checked
AI-PREPARED SUMMARY
Regulatory safety assessment.
4Reduction of immunoreactive ACTH in plasma following intravenous administration of delta sleep-inducing peptide in manAbstract checked
AI-PREPARED SUMMARY
In a double-blind crossover study of 11 healthy men, intravenous DSIP lowered ACTH-like immunoreactivity for at least three hours, while measured cortisol outcomes were unchanged.
Endocrine change does not establish sleep benefit
Eleven healthy men showed lower ACTH-like immunoreactivity after IV DSIP, without a corresponding cortisol change. This endocrine experiment did not demonstrate a clinical sleep benefit.
Additional research · Checked 2026-10-12
5PepPedia: reported practices (accessed October 12, 2026)Community source checked
AI-PREPARED SUMMARY
Secondary editorial account of discussed practices; not a clinical trial or representative survey.
6Research catalog: labeled quantitiesCatalog checked
AI-PREPARED SUMMARY
Lists 2 mg and 5 mg powder-vial configurations. Quantity examples only; vendor quality and suitability are not endorsed.
7Cayman Chemical: Emideltide acetate product informationCatalog checked
AI-PREPARED SUMMARY
Manufacturer chemistry sheet gives the nonapeptide identity, parent formula and 848.8 molecular weight; laboratory material, not human-use preparation instructions.
8Stroke Recovery in Rats (2021)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Rat motor recovery improved after stroke, while infarct size did not significantly change.
Reported population / model
Rats
Reported study details
120 μg/kg nasal · 7 days · Enhanced motor recovery
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Chronic Insomnia Double-Blind Study (1991)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: A small crossover insomnia study reportedly improved objective sleep efficiency and latency, with less convincing subjective benefit.
Reported population / model
Human
Reported study details
15-30 nmol · 6 consecutive nights · Improved sleep efficiency
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
10Endocrine Modulation Research (1988)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source summarizes changes in ACTH, cortisol and GH across heterogeneous experiments; it does not define a consistent clinical effect.
Reported population / model
Human/Animal
Reported study details
Various doses · Multiple studies · Hormone regulation
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
11Chronic Pain Pilot Study (1984)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Six of seven participants reportedly had lower chronic pain and depressive symptoms in an uncontrolled pilot.
Reported population / model
Human
Reported study details
25 nmol IV · 10 days · 6/7 patients improved
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
12Alcohol and Opioid Withdrawal (1984)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Clinical reports describe better sleep and less anxiety during alcohol or opioid withdrawal; controlled effectiveness is not established by the card.
Reported population / model
Human
Reported study details
Variable doses · 5-10 days · Symptom reduction
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
13Sleep Pressure Induction Study (1983)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports 59% more sleep during a 130-minute observation and better later sleep efficiency after an IV dose.
Reported population / model
Human
Reported study details
25 nmol/kg IV · Single dose · 59% sleep increase
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
14Pep-Pedia: DSIP — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 8 min and a peak time of 30 min. Stated attribution: Graf et al.. This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
15Pep-Pedia: DSIP — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12